About Dr. Nagendra S Ningaraj
Dr. Nagendra S Ningaraj has succeeded in transforming challenges into great opportunities for
the organizations, that he has served.
He has thrived on managerial and collaborative role in a multifunctional team environment with
passion and innovation. He also had leadership roles in preclinical, immune and clinical
projects at University of Kansas-Pharmacy School, Cedars-Sinai, Vanderbilt University, Memorial
Health University, Mercer University Medical Centers, Dr. Reddy’s Laboratories, Scintilla
and Scintilla Bio-MARC Pvt. Ltd.
Pharmacology & Toxicology and Medicine Chemistry postdoctoral fellowships at
Directed anti-cancer drug development and medical affairs team for Biologics/biosimilars
Division at Dr. Reddy’s lab- directed a team of 20
Directed clinical collaborations in academic and CRO settings- used preclinical brain
breast cancer models to evaluate toxicity and mechanism:
- MK801 (Merck) -target: Glutamate receptors
- Radiolabeled and non-radiolabeled Temozolomide (Schering-Plough Research Institute):
glioma and delivery to brain tumors
- Sunitinib malate (SUGEN)-target delivery and effect on PDGFR in brain tumors
Performed IVD of infectious (HPV, HCV, HBV, HIV) and non-infectious diseases, validation
molecular and RUO MDx in Oncology at Scintilla Bio-MARC in collaboration with Neuberg
Supratech, a CAP-approved lab on PCR-7500 Dx, FACS and ELISA platforms
Directed Human Tissue banking/ repository
Published more than 75 research articles and presented in many national and
Entrepreneurship- launched Scintilla Academy and Scintilla Bio-MARC Pvt. Ltd.